Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J E M Kitzen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Critical Reviews in Oncology/Hematology|April 17, 2009
Aurora kinase inhibitorsJ J E M Kitzen, M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumoursM J A de Jonge, H Dumez, J J E M Kitzen, et al.
Journal of Occupational Rehabilitation|February 20, 2019
Two-Year Follow-Up of a Multi-centre Randomized Controlled Trial to Study Effectiveness of a Hospital-Based Work Support Intervention for Cancer PatientsS J Tamminga, J H A M Verbeek, M M E M Bos, et al.
Journal of Occupational Rehabilitation|June 16, 2012
A hospital-based work support intervention to enhance the return to work of cancer patients: a process evaluationS J Tamminga, A G E M de Boer, M M E M Bos, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2009
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumoursJ J E M Kitzen, M J A de Jonge, C H J Lamers, et al.
Breast Cancer Research and Treatment|September 8, 2019
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?T G Steenbruggen, N I Bouwer, C H Smorenburg, et al.
Breast Cancer Research and Treatment|January 4, 2021
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?N I Bouwer, T G Steenbruggen, J van Rosmalen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Critical Reviews in Oncology/Hematology|April 17, 2009
Aurora kinase inhibitorsJ J E M Kitzen, M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumoursM J A de Jonge, H Dumez, J J E M Kitzen, et al.
Journal of Occupational Rehabilitation|February 20, 2019
Two-Year Follow-Up of a Multi-centre Randomized Controlled Trial to Study Effectiveness of a Hospital-Based Work Support Intervention for Cancer PatientsS J Tamminga, J H A M Verbeek, M M E M Bos, et al.
Journal of Occupational Rehabilitation|June 16, 2012
A hospital-based work support intervention to enhance the return to work of cancer patients: a process evaluationS J Tamminga, A G E M de Boer, M M E M Bos, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2009
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumoursJ J E M Kitzen, M J A de Jonge, C H J Lamers, et al.
Breast Cancer Research and Treatment|September 8, 2019
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?T G Steenbruggen, N I Bouwer, C H Smorenburg, et al.
Breast Cancer Research and Treatment|January 4, 2021
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?N I Bouwer, T G Steenbruggen, J van Rosmalen, et al.
Pageof 1